Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 10/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19011014 | 1.00 | ALB (0.68) | ALBCA9LMNAPKMTSHR | |
| SCHEMBL25499407 | 0.96 | ALB (0.63) | ALBCA9LMNAPKMTSHR | |
| SCHEMBL19933090 | 0.94 | ALB (0.60) | ALBCA9LMNAL3MBTL1 | |
| SCHEMBL19924294 | 0.94 | ALB (0.60) | ALBCA9LMNAL3MBTL1 | |
| SCHEMBL30540749 | 0.91 | ALB (0.60) | ALBCA9LMNAPKML3MBTL1 | |
| SCHEMBL25499314 | 0.90 | ALB (0.70) | ALBCA9LMNAPKMTSHR | |
| SCHEMBL25499308 | 0.89 | ALB (0.69) | ALBCA9LMNAPKMTSHR | |
| SCHEMBL19924296 | 0.88 | ALB (0.54) | ALBCA9 | |
| SCHEMBL19924298 | 0.88 | ALB (0.54) | ALBCA9 | |
| SCHEMBL26548950 | 0.88 | ALB (0.54) | ALBCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939617-B2 | Functionally modified polypeptides and radiobiosynthesis | IKARIA INC. (US) | 2024-03-26 | — | — | US | claimed |
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| US-11214820-B2 | Functionally modified polypeptides and radiobiosynthesis | IKARIA INC. (US) | 2022-01-04 | — | — | US | claimed |
| WO-2018045376-A2 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IKARIA INC. (US) | 2018-03-08 | — | — | WO | claimed |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2018-03-08 | — | — | US | claimed |
| US-11939617-B2 | Functionally modified polypeptides and radiobiosynthesis | IKARIA INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-08-29 | — | — | US | disclosed |
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
| WO-2022032353-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2022-02-17 | — | — | WO | disclosed |
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11214820-B2 | Functionally modified polypeptides and radiobiosynthesis | IKARIA INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210009715-A1 | NOVEL PSMA-BINDING AGENTS AND USES THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2021-01-14 | — | — | US | disclosed |
| WO-2018045376-A2 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IKARIA INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-2094647-B1 | ALBUMIN BINDING MOLECULES AND USES THEREOF | PHILOCHEM AG (CH) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009715-A1 | NOVEL PSMA-BINDING AGENTS AND USES THEREOF | FOLH1, PSMA3, PSMA2 | ALB 1845/4885CA9 128/4885LMNA 4549/4885 |
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | FIBP, FGFR2, FGFR1 | ALB 1815/4885CA9 2587/4885LMNA 2746/4885 |
| US-11939617-B2 | Functionally modified polypeptides and radiobiosynthesis | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885LMNA 2979/4885 |
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885LMNA 2979/4885 |
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | ALB, TTR, ABCG2 | ALB 1/4885CA9 702/4885LMNA 4231/4885 |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | FIBP, FGFR2, FGFR1 | ALB 1815/4885CA9 2587/4885LMNA 2746/4885 |
| US-11214820-B2 | Functionally modified polypeptides and radiobiosynthesis | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885LMNA 2979/4885 |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885LMNA 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.